10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023

ElSayed, Nuha A., Aleppo, Grazia, Aroda, Vanita R., Bannuru, Raveendhara R., Brown, Florence M., Bruemmer, Dennis, Collins, Billy S., Das, Sandeep R. +14 more·2023·Diabetes Care
DOI 10.2337/dc23-s010

Cited by (453)

Items 101–200 of 453

  1. Lipid Disorders Management Strategies (2024) in Prediabetic and Diabetic Patients
    Laura Gaiţă, Bogdan Timar, Romulus Zorin Timar, Zlatko Fras, Dan Ion Gaiță, Maciej Banach · 2024 · Pharmaceuticals
  2. Updates on dyslipidemia in patients with diabetes
    Shintaro Ide, Yoshiro Maezawa, Koutaro Yokote · 2023 · Journal of Diabetes Investigation
  3. Clinical evaluation of a polarization-based optical noninvasive glucose sensing system
    Ho Man Colman Leung, Chengyue Gong, Luke Geiser, Emily E. Fivekiller, Nam Bui, Tam N. Vu, Temiloluwa Prioleau, Gregory P. Forlenza, Qiang Liu, Xia Zhou · 2025 · Scientific Reports
  4. Management of Type 2 Diabetes in Frail Older Adults
    Gülistan Bahat, Serdar Özkök, Mirko Petrović · 2023 · Drugs & Aging
  5. Association of the Triglyceride–Glucose Index During the First Trimester of Pregnancy with Adverse Perinatal Outcomes
    Guillermo Gurza, Nayeli Martínez-Cruz, Ileana Lizano-Jubert et al. · 2025 · Diagnostics
  6. When cardiovascular medicines should be discontinued
    Konstantin Alexander Krychtiuk, Bernard John Gersh, Jeffrey B. Washam, Christopher Bull Granger · 2024 · European Heart Journal
  7. Effects of albiglutide on myocardial infarction and ischaemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial
    Konstantin Alexander Krychtiuk, Guillaume Marquis‐Gravel, Shannon Murphy, Karen P. Alexander, Karen Chiswell, Jennifer B. Green, Lawrence A. Leiter, Renato D. Lópes, Stefano Del Prato, W. Schuyler Jones et al. · 2024 · European Heart Journal - Cardiovascular Pharmacotherapy
  8. Intake of dietary flavonoids in relation to bone loss among U.S. adults: a promising strategy for improving bone health
    Yi Zheng, Jiacheng Wang, Kelin Xu, Xingdong Chen · 2023 · Food & Function
  9. Sodium glucose cotransporter2 inhibitors for type 1 diabetes mellitus: A meta-analysis of randomized controlled trials
    Juanli Nan, Dekai Wang, Ruxian Zhong, Fen Liu, Jingmei Luo, Ping Tang, Xiaoxiao Song, Lihua Zhang · 2023 · Primary care diabetes
  10. Diabetic Kidney Disease Prevention Care Model Development
    Nuha A. ElSayed, Raveendhara R. Bannuru, George L. Bakris, Joan K. Bardsley, Ian H. de Boer, Robert A. Gabbay, Janet P. Gockerman, Rozalina G. McCoy, Elaine McCracken, Joshua J. Neumiller et al. · 2023 · Clinical Diabetes
  11. Urinary metabolites associate with the presence of diabetic kidney disease in type 2 diabetes and mediate the effect of inflammation on kidney complication
    Caifeng Shi, Yemeng Wan, Aiqin He, Xiaomei Wu, Xinjia Shen, Xueting Zhu, Junwei Yang, Yang Zhou · 2023 · Acta Diabetologica
  12. Management of Hypertension in Patients with Type 2 Diabetes Mellitus: Indian Guideline 2024 by Association of Physicians of India and Indian College of Physicians
    Gurpreet Singh Wander, Jayanta Kumar Panda, Jyotirmoy Pal, Girish Mathur, Rakesh Kumar Sahay, MANGESH HARIHAR TIWASKAR, Nandini Chatterjee, Sekhar Chakrabarty, Devendra Prasad Singh, L. Sreenivasa Murthy et al. · 2024 · Journal of the Association of Physicians of India
  13. Non‐steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes
    Carolina Solis‐Herrera, Curtis L. Triplitt · 2023 · Diabetes Obesity and Metabolism
  14. Clinical care guidance in patients with diabetes and metabolic dysfunction–associated steatotic liver disease: A joint consensus
    Jee‐Fu Huang, Tien‐Jyun Chang, Ming‐Lun Yeh, Feng‐Chih Shen, Chi‐Ming Tai, Jung‐Fu Chen, Yi‐Hsiang Huang, Chih‐Yao Hsu, Pin‐Nan Cheng, Ching‐Ling Lin et al. · 2024 · Hepatology Communications
  15. Nighttime administration of antihypertensive medication: a review of chronotherapy in hypertension
    Hyun‐Jin Kim, Sang‐Ho Jo · 2023 · The Korean Journal of Internal Medicine
  16. Risk factors for and risk of all-cause and atherosclerotic cardiovascular disease mortality in people with type 2 diabetes and peripheral artery disease: an observational, register-based cohort study
    Tarik Avdic, Hanne Krage Carlsen, Aidin Rawshani, Soffia Guðbjörnsdóttir, Zacharias Mandalenakis, Björn Eliasson · 2024 · Cardiovascular Diabetology
  17. Effect of finerenone on nephrotic syndrome in patients with diabetic kidney disease
    Akira Mima, Yuta Saito, Keishi Matsumoto, Takahiro Nakamoto, Shinji Lee · 2024 · Metabolism Open
  18. Validation and comparison of cardiovascular risk prediction equations in Chinese patients with Type 2 diabetes
    Jingyuan Liang, Qianqian Li, Zhangping Fu, Xiaofei Liu, Peng Shen, Yexiang Sun, Jingyi Zhang, Ping Lu, Hongbo Lin, Xun Tang et al. · 2023 · European Journal of Preventive Cardiology
  19. The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review
    André Jacques Scheen · 2023 · Expert Review of Endocrinology & Metabolism
  20. Assessment of Cardiovascular Risk Categories and Achievement of Therapeutic Targets in European Patients with Type 2 Diabetes
    Delia Reurean‐Pintilei, Claudia-Gabriela Potcovaru, Teodor Salmen, Liliana Mititelu-Tarțău, Delia Cinteză, Sandra Lazăr, Anca Pantea Stoian, Romulus Zorin Timar, Bogdan Timar · 2024 · Journal of Clinical Medicine
  21. Epidemiology of the first-ever cardiovascular event in people with type 1 diabetes: a retrospective cohort population-based study in Catalonia
    Gabriel Giménez‐Pérez, Clara Viñals, Manel Mata‐Cases, Bogdan Vlacho, Jordi Real, Josep Franch‐Nadal, Emilio Ortega, Dı́dac Mauricio · 2023 · Cardiovascular Diabetology
  22. New Perspectives in Management of Cardiovascular Risk Among People With Diabetes
    Abhishek Gami, Roger Scott Blumenthal, Darren K. McGuire, Sudipa Sarkar, Payal Kohli · 2024 · Journal of the American Heart Association
  23. Combined Sodium-Glucose-Transporters Inhibitors and Glucagon-Like-Peptide Receptor Agonist Compared With Monotherapy Improves Long-Term Survival: A Real-World Registry
    David García‐Vega, Sergio Cinza‐Sanjurjo, Sonia Eirás, José Ramón González‐Juanatey · 2024 · The American Journal of Medicine
  24. Unraveling atherosclerotic cardiovascular disease risk factors through conditional probability analysis with Bayesian networks: insights from the AZAR cohort study
    Parya Esmaeili, Neda Roshanravan, Samad Ghaffari, Naimeh Mesri Alamdari, Mohammad Asghari Jafarabadi · 2024 · Scientific Reports
  25. Risk of Stroke in Real-World US Individuals with Type 2 Diabetes Receiving Semaglutide or a Dipeptidyl Peptidase 4 Inhibitor
    Evans, Marc, Husain, Mansoor, Srivastava, Ayush, Mangla, Kamal Kant, Kuhlman, Anja Birk, Lingvay, Ildiko · 2024 · Advances in Therapy
  26. The Pharmaceutical Potential of α- and β-Amyrins
    Tran Duc Viet, La Hoang Anh, Tran Dang Xuan, Ngo Duy Dong · 2025 · Nutraceuticals
  27. Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data
    Ronald Goldenberg, Hwee Teoh, Subodh Verma · 2023 · Current Opinion in Cardiology
  28. Lifetime and 10‐year cardiovascular risk prediction in individuals with type 1 diabetes: The LIFE‐T1D model
    Marga A. G. Helmink, Steven H J Hageman, Björn Eliasson, Naveed A. Sattar, Frank L.J. Visseren, Jannick A N Dorresteijn, Katie Harris, Sanne A. E. Peters, Mark Woodward, Péter Szentkúti et al. · 2024 · Diabetes Obesity and Metabolism
  29. Statin therapy and cardiovascular protection in type 2 diabetes: The role of baseline LDL-Cholesterol levels. A systematic review and meta-analysis of observational studies
    Negin Soroush, Mitra Nekouei Shahraki, Soroush Mohammadi Jouabadi, Masoud Amiri, Elif Aribas, Bruno H. Ch. Stricker, Fariba Ahmadizar · 2024 · Nutrition Metabolism and Cardiovascular Diseases
  30. Current views on selenoprotein S in the pathophysiological processes of diabetes-induced atherosclerosis: potential therapeutics and underlying biomarkers
    Shanshan Yu, DU Jian-ling · 2024 · Diabetology & Metabolic Syndrome
  31. Assisted reproductive technology: what are the cardiovascular risks for women?
    Carolyn S. Guan, Carla P. Rodriguez, Petal Elder-Odame, Anum Minhas, Salman Zahid, Valerie Lynn Baker, CHRISANDRA L. SHUFELT, Erin D. Michos · 2023 · Expert Review of Cardiovascular Therapy
  32. Cardiovascular and renal outcomes with SGLT2 inhibitors: Real-life observational studies in older patients with type 2 diabetes
    André Jacques Scheen · 2023 · Diabetes Epidemiology and Management
  33. Diabetes and the risk of cardiovascular events and all‐cause mortality among older adults: an individual participant data analysis of five prospective studies
    Valerie Aponte Ribero, Orestis Efthimiou, Nazanin Abolhassani, Heba Alwan, Douglas C. Bauer, Séverine Henrard, Antoine Christiaens, Denis O’Mahony, Wilma Knol, Mike J.L. Peters et al. · 2024 · European Journal of Clinical Investigation
  34. Prevalence of dyslipidemia among persons with type 2 diabetes in Africa: a systematic review and meta-analysis
    Emmanuel Ekpor, Dorothy Addo‐Mensah, Samuel Akyirem · 2024 · Annals of Medicine and Surgery
  35. SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus
    Nikola Lukic, Mirjana Mačvanin, Zoran M. Gluvic, Manfredi Rizzo, Djordje J. Radak, Jasjit S. Suri, Esma R. Isenović · 2023 · Current Medicinal Chemistry
  36. Association between estimated glucose disposal rate and future cardiovascular disease risk across glucose metabolism status: a prospective cohort study
    Xiaomin Liang, Kai Lai, Xiaohong Li, Di Ren, Shuiqing Gui, Zemao Xing, Ying Li · 2025 · Diabetology & Metabolic Syndrome
  37. Deficiency of Peptidylglycine-alpha-amidating Monooxygenase, a Cause of Sarcopenic Diabetes Mellitus
    Alice Giontella, Mikael Åkerlund, Kevin Bronton, Cristiano Fava, Luca Andrea Lotta, Aris Baras, John D. Overton, Marcus Jones, Andreas Bergmann, Paul Kaufmann et al. · 2024 · The Journal of Clinical Endocrinology & Metabolism
  38. Unexplained Residual Risk In Type 2 Diabetes: How Big Is The Problem?
    Sivaram Neppala, Jemema Rajan, Eric Yang, Ralph A. DeFronzo · 2024 · Current Cardiology Reports
  39. Long-term Effectiveness of the National Diabetes Quality Assessment Program in South Korea
    Ji Hye Huh, Serim Kwon, Gui Ok Kim, Bo‐Yeon Kim, Kyoung Hwa Ha, Dae Jung Kim · 2023 · Diabetes Care
  40. Microbiological characterization of neuropathic diabetic foot infection: a retrospective study at a Portuguese tertiary hospital
    2024
  41. Should We “RESPECT EPA” More Now? EPA and DHA for Cardiovascular Risk Reduction
    Michelle D. Kelsey, Neha Jadeja Pagidipati · 2023 · Current Cardiology Reports
  42. Risk Factors for and Risk of Peripheral Artery Disease in Swedish Individuals With Type 2 Diabetes: A Nationwide Register-Based Study
    Tarik Avdic, Hanne Krage Carlsen, Rikard Isaksson, Soffia Guðbjörnsdóttir, Zacharias Mandalenakis, Stefan Franzén, Naveed A. Sattar, Joshua A. Beckman, Darren K. McGuire, Björn Eliasson · 2023 · Diabetes Care
  43. Management of type 2 diabetes in the new era
    Aris Liakos, Thomas Karagiannis, Ioannis Avgerinos, Konstantinos Malandris, Απόστολος Τσάπας, Eleni Bekiari · 2023 · HORMONES
  44. Trajectories of clinical characteristics, complications and treatment choices in data-driven subgroups of type 2 diabetes
    Xinyu Li, Louise A. Donnelly, Roderick C. Slieker, Joline W. J. Beulens, Leen M. ‘t Hart, Petra J. M. Elders, Ewan R. Pearson, Anoukh van Giessen, José Leal, Talitha Feenstra · 2024 · Diabetologia
  45. Distinct effects of rosuvastatin and rosuvastatin/ezetimibe on senescence markers of CD8+ T cells in patients with type 2 diabetes mellitus: a randomized controlled trial
    Sang Hyeon Ju, Joung Youl Lim, Minchul Song, Ji Min Kim, Yea Eun Kang, Hyon‐Seung Yi, Kyong Hye Joung, Ju Hee Lee, Hyun Jin Kim, Bon Jeong Ku · 2024 · Frontiers in Endocrinology
  46. Association of dietary patterns with diabetes-related comorbidities varies among diabetes endotypes
    Katharina Susanne Weber, Sabrina Schlesinger, Alexander Lang, Klaus Straßburger, Haïfa Maalmi, Anna Zhu, Oana‐Patricia Zaharia, Alexander Strom, Gidon Josia Bönhof, Janina Goletzke et al. · 2024 · Nutrition Metabolism and Cardiovascular Diseases
  47. Cardiovascular Events in Adults with Type 2 Diabetes and ASCVD Initiating Once-Weekly Semaglutide vs DPP-4is in the USA
    Silvio E. Inzucchi, Xi Tan, Yuanjie Michael Liang, Larisa Yedigarova, Lin Xie, Adam de Havenon · 2024 · Diabetes Therapy
  48. Gut Molecules in Cardiometabolic Diseases: The Mechanisms behind the Story
    Andreea-Ioana Inceu, Maria Adriana Neag, Anca Elena Craciun, Anca Dana Buzoianu · 2023 · International Journal of Molecular Sciences
  49. Lipid-lowering therapy and LDL target attainment in type 2 diabetes: trends from the Italian Associations of Medical Diabetologists database
    Antonio Rossi, Davide Masi, Rita Zilich et al. · 2025 · Cardiovascular Diabetology
  50. Sex inequalities in cardiovascular risk factors and their management in primary prevention in adults living with type 1 diabetes in Germany and France: findings from DPV and SFDT1
    Emmanuel Cosson, Marie Auzanneau, Gloria Aguayo, Wölfram Karges, Jean‐Pierre Riveline, Petra Augstein, Laura Sablone, Peter Michael Jehle, Guy Fagherazzi, Reinhard Walter Holl et al. · 2024 · Cardiovascular Diabetology
  51. Targeting obesity for therapeutic intervention in heart failure patients
    Ryosuke Sato, Stephan von Haehling · 2024 · Expert Review of Cardiovascular Therapy
  52. A Real-World Precision Medicine Program Including the KidneyIntelX Test Effectively Changes Management Decisions and Outcomes for Patients With Early-Stage Diabetic Kidney Disease
    Joji Erik Tokita, David Wing-Hang Lam, Aida Vega, Stephanie Y. Wang, Leonard Amoruso, T Müller, Nidhi Naik, Shivani Rathi, Sharlene Martin, Azadeh Zabetian et al. · 2024 · Journal of Primary Care & Community Health
  53. Glucagon-like peptide-1 receptor agonists: a review from a cardiovascular perspective
    Turkistani, Yosra · 2025 · Frontiers in Cardiovascular Medicine
  54. Evaluation of Limbal Stem Cells in Patients With Type 2 Diabetes: An In Vivo Confocal Microscopy Study
    Chen, Dan, Wang, Leying, Guo, Xiaoyan · 2024 · Cornea
  55. 2024 The Royal College of Physicians of Thailand (RCPT) clinical practice guidelines on management of dyslipidemia for atherosclerotic cardiovascular disease prevention
    Praween Lolekha, Weerapan Khovidhunkit, Chaicharn Deerochanawong, Nuntakorn Thongtang, Thananya Boonyasirinant, Chatchalit Rattarasarn, Aurauma Chutinet, Vuddhidej Ophascharoensuk, Nicha Somlaw, Surapun Sitthisook et al. · 2024 · Asian Biomedicine
  56. Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: A post hoc analysis of the SUSTAIN 6 randomized controlled trial
    Jingyu Wang, Juhong Yang, Wenhui Jiang, Wenyan Liu, Zewei Shen, Zhongai Gao, Baocheng Chang · 2024 · Diabetes Obesity and Metabolism
  57. Type 2 Diabetes and Chronic Kidney Disease: An Opportunity for Pharmacists to Improve Outcomes
    Joshua J. Neumiller, Wendy L. St. Peter, Jay H. Shubrook · 2024 · Journal of Clinical Medicine
  58. The effect of breakfast skipping and sleep disorders on glycemic control, cardiovascular risk, and weight loss in type 2 diabetes
    Tatiana Palotta Minari, Carolina Freitas Manzano, Louise Buonalumi Tácito Yugar, Luis Gustavo Sedenho‐Prado, Tatiane de Azevedo Rubio, Lúcia Helena Bonalume Tácito, Antônio Carlos Pires, José Fernando Vilela-Martin, Luciana Neves Cosenso‐Martin, Nelson Dinamarco Ludovico et al. · 2024 · Clinical Nutrition ESPEN
  59. Association Between Age at Diagnosis of Type 2 Diabetes and Hospitalization for Heart Failure: A Population‐Based Study
    Calvin Ke, Baiju R. Shah, Deva Thiruchelvam, Justin Basile Echouffo-Tcheugui · 2024 · Journal of the American Heart Association
  60. Trajectory of lung function in diabetic adults: A 16‐year follow‐up study of community‐based prospective cohorts
    Choi, Wonsuk, Moon, Joon Ho, Choi, Hayoung · 2024 · Respirology
  61. Progression to Insulin Therapy in Patients With Type 2 Diabetes According to Cardiorespiratory Fitness, Body Mass Index, and Statin Therapy
    Peter F Kokkinos, Eric Nylén, Charles J. Faselis, Andreas E. Pittaras, Immanuel Babu Henry Samuel, Carl J. Lavie, Michael N. Doumas, Michael S. Heimall, Rayelynn Murphy, JONATHAN N. MYERS · 2023 · Mayo Clinic Proceedings
  62. ELUCIDATE Trial: A Single‐Center Randomized Controlled Study
    Jiun‐Lu Lin, Sung-Chen Liu, T Liu, Shih‐Ming Chuang, Chun‐Ta Huang, Y.-J. Chen, Chun‐Chuan Lee, Ming-Nan Chien, Charles Jia‐Yin Hou, Hung‐I Yeh et al. · 2024 · Journal of the American Heart Association
  63. Fenofibrate’s impact on cardiovascular risk in patients with diabetes: a nationwide propensity-score matched cohort study
    Sangmo Hong, Kyung‐Soo Kim, Kyungdo Han, Cheol‐Young Park · 2024 · Cardiovascular Diabetology
  64. Triglyceride‐glucose index trajectories predict adverse cardiovascular outcomes in elderly heart failure patients with Diabetes: A retrospective cohort study
    Hong Liu, Jian Wang, Luo Zhi · 2024 · Aging Medicine
  65. The role of atherogenic lipoproteins in diabetes: Molecular aspects and clinical significance
    Yajnavalka Banerjee, Angelo Maria Patti, Rosaria Vincenza Giglio, Marcello Ciaccio, Suhina Vichithran, Shemima Faisal, Anca Pantea Stoian, Ali Abbas Rizvi, Manfredi Rizzo · 2023 · Journal of Diabetes and its Complications
  66. UpToDate®
    2023 · The Nurse Practitioner
  67. Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups: Insights From the COORDINATE-Diabetes Trial
    Manasi Tannu, Lisa A. Kaltenbach, Neha Jadeja Pagidipati, Darren K. McGuire, Vanita R. Aroda, Rodica Pop‐Busui, Nitin Kondamudi, Hussein R. Al‐Khalidi, Renato D. Lópes, Matthew Aaron Cavender et al. · 2024 · Circulation
  68. Impact of coronary artery calcium on mortality and cardiovascular events in metabolic syndrome and diabetes among younger adults
    Soroush Masrouri, Michael David Shapiro, Davood Khalili, Farzad Hadaegh · 2024 · European Journal of Preventive Cardiology
  69. Pretreatment body mass index affects achievement of target blood pressure with sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease
    Shunichiro Tsukamoto, Kazuo Kobayashi, Masao Toyoda, Nobuo Hatori, Tomohiko Kanaoka, Hiromichi Wakui, Hiroyuki Sakai, Takayuki Furuki, Keiichi Chin, Shun Ito et al. · 2023 · Hypertension Research
  70. An Artificial Intelligence-Based Fuzzy Logic System for Periodontitis Risk Assessment in Patients with Type 2 Diabetes Mellitus
    Ioana Scrobotă, Gilda Mihaela Iova, Olivia Andreea Marcu, Liliana Sachelarie, Silviu Valentin Vlad, Ioana Monica Duncea, Florin Blaga · 2025 · Bioengineering
  71. Glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter 2 inhibitor use among adults with diabetes mellitus by cardiovascular-kidney disease risk: National Health and Nutrition Examination Surveys, 2015–2020
    Joshua A. Jacobs, Alexander R. Zheutlin, Catherine G. Derington, Jordan B. King, Ambarish Pandey, Adam Phillip Bress · 2023 · American Journal of Preventive Cardiology
  72. Hyperlipidaemia in diabetes: are there particular considerations for next-generation therapies?
    Sophie Béliard, Florian Mourre, René Valéro · 2024 · Diabetologia
  73. Navigating the Digital Landscape of Diabetes Care: Current State of the Art and Future Directions
    Helena Gonçalves, Firmino Oliveira da Silva, Catarina Rodrigues, António Lencastre Godinho · 2024 · Procedia Computer Science
  74. Trends in prescribing sodium‐glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular‐renal disease in South Korea, 2015–2021
    Kyoung Hwa Ha, So–Youn Shin, EunJi Na, Dae Jung Kim · 2024 · Journal of Diabetes Investigation
  75. Short-term glucose variability as a determinant of the healing rate of diabetic foot ulcer: A retrospective study
    Paola Caruso, Lorenzo Scappaticcio, Maurizio Gicchino, Filomena Castaldo, Mariluce Barrasso, Carla Carbone, Mariangela Caputo, Maria Tomasuolo, Vanda Amoresano Paglionico, Giuseppe Bellastella et al. · 2024 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
  76. Comparative efficacy of GLP-1 RAs/SGLT-2 inhibitors in reducing cardiovascular events in type 2 diabetes according to baseline use of metformin: a systematic review and meta-analysis of randomized controlled trials
    Yuxin Zhang, Zhaoji Li, Yongchen Hao · 2025 · European journal of medical research
  77. Insights into the impact of sodium‐glucose cotransporter 2 inhibition on urinary tract malignancy: A two‐sample Mendelian randomization
    Zeyu Han, Yazhou He, Xue Li, Sheyu Li, Jianzhong Ai · 2024 · Diabetes Obesity and Metabolism
  78. Metabolic/bariatric surgery optimization: a position statement by Arabic association for the study of diabetes and metabolism (AASD)
    Amin Roshdy Soliman, Hesham Magd eldin Saleem, Amr Abdel Hady El Meligi, Mervat Naguib, Rasha Sobh Mohamed, Ghada Rabie Abdelaziz, Maha Rakha, Shereen Abdelghaffar, Abd Elkhalek Hamed, Hany Hammad et al. · 2025 · Diabetology & Metabolic Syndrome
  79. Prescription medication use among patients with type 2 diabetes in the United States: 1999–2020
    Shanshan Li, Shaoxi Pan, Shaoxiang Jiang, Jung‐Im Shin, Gordon G. Liu, Beini Lyu · 2024 · Diabetes Obesity and Metabolism
  80. Comorbidities and neighborhood factors associated with prescription of sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists among medically underserved populations
    Deborah Ogunsanmi, Austin Harrison, Avinash Reddy Pakker, Csaba Pal Kovesdy, James E Bailey, Satya Surbhi · 2023 · Journal of Managed Care & Specialty Pharmacy
  81. Is Tirzepatide the New Game Changer in Type 2 Diabetes?
    Giuseppe Lisco, Olga Disoteo, Vincenzo De Geronimo, Anna De Tullio, Vito Angelo Giagulli, Edoardo Guastamacchia, Giovanni De Pergola, Emilio Jirillo, Vincenzo Triggiani · 2024 · Endocrines
  82. Diabetes and Stroke: Impact of Novel Therapies for the Treatment of Type 2 Diabetes Mellitus
    Inês Henriques Vieira, Tânia Carvalho, Joana C. Saraiva, Leonor Gomes, Isabel Paiva · 2024 · Biomedicines
  83. Influence of the duration of type 2 diabetes mellitus on colorectal cancer outcomes
    Magdolna Herold, Attila Marcell Szász, Gyöngyvér Szentmártoni, Emoke Martinek, Viktor Madar-Dank, Andras Jozsef Barna, Réka Mohácsi, Anikó Somogyi, Magdolna Dank, Zoltán Herold · 2023 · Scientific Reports
  84. Low-Density Lipoprotein Cholesterol, Type 2 Diabetes and Progression of Aortic Stenosis: The RED-CARPET Heart Valve Subgroup Cohort Study
    Jingjing He, Zhenyu Xiong, Odong Christopher, Zhuoshan Huang, Chaoguang Xu, Menghui Liu, Miaohong Li, Zhen Guo, Xinxue Liao, Xiaodong Zhuang · 2024 · Reviews in Cardiovascular Medicine
  85. Increasing the complexity of lipoprotein characterization for cardiovascular risk in type 2 diabetes
    Montse Guardiola, Pere Rehues, Núria Amigó, Francisco Arrieta, Manuel Botana, José Antonio Gimeno-Orna, Josefa Girona, José Ignacio Martínez‐Montoro, Emilio Ortega, Antonio Pérez et al. · 2024 · European Journal of Clinical Investigation
  86. Advances and counterpoints in type 2 diabetes. What is ready for translation into real-world practice, ahead of the guidelines
    Stanley S. Schwartz, Barbara E. Corkey, James R. Gavin, Ralph A. DeFronzo, Mary E. Herman · 2024 · BMC Medicine
  87. High detectable and low sample volume portable cholesterol biosensor based on PAMAM dendrimers grafted to bioinspired polynorepinephrine nanomaterials
    Jędrzak, Artur, Kuznowicz, Maria, Hoffa, Katarzyna · 2025 · Journal of Applied Electrochemistry
  88. Type 2 Diabetes: Etiology, Epidemiology, Pathogenesis, and Treatment
    Carrie Burns, Nnenia Francis · 2023 · Springer eBooks
  89. Guideline concordance of aspirin use for primary prevention in adult outpatients
    Naina Chipalkatti, Geoffrey D. Barnes, Linda Bashaw et al. · 2024 · Blood Advances
  90. Use of Continuous Glucose Monitoring and Glucagon-Like Peptide 1 Receptor Agonist Therapy to Achieve Individualized Treatment Goals in Insulin-Treated People With Type 2 Diabetes: A Case Series and Expert Opinion
    Nicole M Ehrhardt, Vanita R. Aroda, Rodolfo Javier Galindo, Anne L. Peters, Jay H. Shubrook · 2023 · Clinical Diabetes
  91. Association between all-cause mortality and vascular complications in U.S. adults with newly diagnosed type 2 diabetes (NHANES 1999–2018)
    Tianyu Zhang, Xuening Wang, Hongyu Kuang · 2024 · Acta Diabetologica
  92. Severe hypoglycemia and hypoglycemia awareness are associated with preclinical atherosclerosis in patients with type 1 diabetes without an estimated high cardiovascular risk
    Alex Mesa, Marga Giménez, Verónica Perea, Tonet Serés‐Noriega, Laura Boswell, Jesús Blanco, Camila Milad, Adriana Pané, Enric Esmatjes, Irene Vinagre et al. · 2024 · Diabetes/Metabolism Research and Reviews
  93. Out-of-pocket direct cost of ambulatory care of type 2 diabetes in Delhi: Estimates from the Delhi diabetes community-II (DEDICOM-II) survey
    2024
  94. Associations of Sleep Quality and Physical Activity with Diabetes Quality of Life in Korean Americans with Type 2 Diabetes: A Cross-Sectional Study
    Mihyun Jeong · 2024 · Healthcare
  95. Incident Cardiovascular Disease in Women With Type 1 or Type 2 Diabetes Following a Hypertensive Disorder of Pregnancy
    Kristina Mattsson, Mats Pihlsgård, Sofia Enhörning, Simon Timpka · 2024 · Hypertension
  96. Association of Strict Versus Lenient Cholesterol Lowering with Cardiac Outcomes, Diabetes Progression and Complications, and Mortality in Patients with Diabetes Treated with Statins: Is Less More?
    Victoria Odeleye, Omar Masarweh, Jorge Restrepo, Carlos A. Álvarez, Ishak A. Mansi · 2023 · Drug Safety
  97. Pasireotide-induced hyperglycemia in Cushing’s disease and Acromegaly: A clinical perspective and algorithms proposal
    Przemysław Witek, Marek Bolanowski, Adam Jacek Kretowski, Aleksandra Głowińska · 2024 · Frontiers in Endocrinology
  98. Correlation between non-alcoholic fatty liver disease and metabolic parameters in persons with newly diagnosed type 2 diabetes mellitus
    Supriyo Mukherjee, Sushmita Mukherjee, Chun Shing Kwok, Anne Phillips · 2024 · World Journal of Hepatology
  99. Association of total cholesterol to high-density lipoprotein cholesterol ratio with diabetes risk: a retrospective study of Chinese individuals
    Zhiqiang Zhang, Hejun Chen, Lei Chen, Wenyan Liang, Tenglong Hu, Na Sun, Yangyu Zhao, Xiqing Wei · 2025 · Scientific Reports
  100. Pilot trial results of D-HOMES: a behavioral-activation based intervention for diabetes medication adherence and psychological wellness among people who have been homeless
    Katherine Diaz Vickery, Lillian Gelberg, Audrey Rose Hyson, Ella Strother, Jill Carter, Oscar Oranday Perez, Moncies Franco, Silvio Kavistan, Susan Gust, Edward Adair et al. · 2024 · Frontiers in Psychiatry